Boxun Lu
Professor Fudan University
I’m currently working on discovering de novo therapeutic targets for Huntington’s Disease (HD). HD is the third most prevalent neurodegenerative diseases, as well as the most prevalent CAG triplet disorder.
I’ve utilized high-throughput technologies to perform the genome-wide screenings for genetic targets that degrade the mutant protein which causes the disease. I further validated the hits in human patient cells, as well as other mammalian cellular HD models, including human ESC/iPSC models. I then performed the pathway analysis and designed experiments to reveal the molecular pathways that degrade the disease protein, as well as the physiological significance of the targets/pathways. In addition, I’ve characterized the ESC/iPSC derived neuronal models and revealed insights of the mechanisms of disease pathology.
Seminars
- Explore how Fudan University has established an endocytosis-independent TPD technology for transmembrane proteins
- Discuss how the technology achieved pM-nM DC50 and >90% Dmax for PD-L1 by small molecule degraders
- Assess how it also achieved significantly better efficacy in vivo than clinical PD-L1 antibodies
